Exchange: NASDAQ·Updated 06:00 PM EDT
Latest Earnings Results: Q1 '26

Reported: Feb 24

Estimated EPS

-$0.11

Reported EPS

---

Surprise

---

Estimated Rev

$59.3M

Reported Rev

---

Surprise

---

$DAWN Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.21 up 69.57% YoY • Reported revenue of $53.72M up 83.92% YoY • Day One Biopharmaceuticals expects to complete enrollment of the pivotal Phase 3 FIREFLY-2 trial, evaluating tovorafenib as a front-line therapy in pLGG, in the first half of 2026.

Generated by Stocktwits using AI and company-reported earnings data for Q1 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q2 '26
-$0.10
--
--
N/A
Q1 '26
-$0.11
--
--
N/A
Q4 '25
-$0.15
-$0.21
-41.06%
MISSED
Q3 '25
-$0.30
-$0.19
36.00%
BEAT
Q2 '25
-$0.36
-$0.29
18.66%
BEAT

Advertisement|Remove ads.